Researchers are making discoveries every day at the Vera Bradley Foundation for Breast Cancer Research Laboratories at Indiana University Melvin and Bren Simon Cancer Center. Meet Milan Radovich, Ph.D., a history buff, golf enthusiast ... and a translational research scientist who is passionate about getting to know his patients.
Milan Radovich, Ph.D., grew up in Chicago, the son of Serbian immigrants. His father left the former Yugoslavia due to his family’s anti-Communist stance and served in the British army as a member of NATO before coming to the U.S. His mother left Serbia in search of the American dream. With their two sons, they both placed a strong emphasis on education. Neither spoke English well, forcing a young Milan to ask lots of questions and seek answers on his own in order to excel. Today, he uses those same investigative skills in his pursuit of innovative treatments and solutions for breast cancer as one of the newest members of the Vera Bradley Foundation for Breast Cancer Research Laboratories. Milan is a translational research scientist and is passionate about getting to know patients and making discoveries that will directly impact their care. In fact, his mentors are doctors who treat patients and conduct research—notably Drs. George Sledge, Bryan Schneider and Susan Clare. “They help me focus on answering pertinent clinical questions that will have a true impact on treating breast cancer patients,” he explains. Milan spends most of his spare time with his wife, Betsy, and their 5-year-old daughter, Grace. A history buff, he’s also involved with several men’s groups at church, mentors young fathers, and tries to squeeze in a round of golf when he can.
After earning his doctorate degree this year, Milan chose to remain at IU, where he can focus on breast cancer and pursue ideas with the potential to transform care. His start-up package, which helps pay for his lab and three-member team, is funded in part with money from the Vera Bradley Foundation for Breast Cancer.
Milan’s research focuses on Triple Negative breast cancer, a particularly deadly and aggressive form of the disease. His primary work involves using cutting-edge genomics technologies to determine the differences between triple-negative breast cancer and the normal breast in order to exploit these differences for drug development, methods of early detection, and discovering the mutational causes of this disease.